HighVista Strategies’s Amicus Therapeutics FOLD Stock Holding History

HighVista Strategies’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-62,581	Closed	-$786K	–	147
2023 Q2	$786K	Sell	62,581 -14,733	-19%	-$175K	0.36%	70
2023 Q1	$857K	Hold	77,314	–	–	0.7%	45
2022 Q4	$944K	Buy	77,314 +8,484	+12%	+$95.5K	0.56%	47
2022 Q3	$719K	Sell	68,830 -21,404	-24%	-$238K	0.41%	67
2022 Q2	$969K	Sell	90,234 -18,023	-17%	-$148K	0.59%	38
2022 Q1	$1.02M	Sell	108,257 -5,130	-5%	-$48.1K	0.65%	33
2021 Q4	$1.31M	Hold	113,387	–	–	1.04%	30
2021 Q3	$1.08M	Buy	113,387 +29,016	+34%	+$297K	0.72%	48
2021 Q2	$813K	Buy	+84,371	New	+$824K	0.58%	42
2021 Q1	–	Sell	-39,774	Closed	-$918K	–	132
2020 Q4	$918K	Buy	39,774 +6,881	+21%	+$141K	0.59%	33
2020 Q3	$464K	Buy	32,893 +6,030	+22%	+$87.9K	0.34%	57
2020 Q2	$405K	Buy	+26,863	New	+$327K	0.34%	63

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

HighVista Strategies's FOLD Position: Q3 2023 in Review

HighVista Strategies sold out of Amicus Therapeutics (FOLD) in Q3 2023, closing a stake of 62,581 shares — an estimated $786K sold.

HighVista Strategies first reported a position in FOLD in Q2 2020 and held it in 12 quarters. The position peaked at $1.31M in Q4 2021. 228 funds tracked by Wall St. Rank hold FOLD as of Q3 2023.

HighVista Strategies reported no remaining Amicus Therapeutics position as of Q3 2023 after selling out during the quarter.
HighVista Strategies sold 62,581 Amicus Therapeutics shares in Q3 2023, an estimated $786K.
HighVista Strategies first reported a position in Amicus Therapeutics in Q2 2020 and held it in 12 quarters.
HighVista Strategies's Amicus Therapeutics position peaked at $1.31M in Q4 2021.
228 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2023.

Based on HighVista Strategies's 13F filing for Q3 2023, filed 14 Nov 2023.